Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery and maximal regional chemotherapy, has been applied to treat ovarian cancer resulting in long-term survival rates in selected patients. However, the status of HIPEC in ovarian cancer remains an experimental procedure, given the many variables among the data and trials reviewed, to enable us to derive strong conclusions about its role from this overview. In this review we discuss treatment with HIPEC in patients with ovarian cancer and future prospective of its use in clinical setting. HIPEC is an effective tool in the treatment of selected patients with peritoneal carcinomatosis from ovarian cancer. Unfortunately, due to the lack of randomised trials, the evidence of HIPEC is very limited. Future randomised studies are awaited to define the role and clinical impact of HIPEC in ovarian cancer
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer / Polom Karol; Roviello Giandomenico; Generali Daniele; Marano Luigi; Petrioli Roberto; Marsili Stefania; Caputo Edda; Marrelli Daniele; Roviello Franco. - In: INTERNATIONAL JOURNAL OF HYPERTHERMIA. - ISSN 0265-6736. - STAMPA. - 32:(2016), pp. 298-310. [10.3109/02656736.2016.1149233]
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer
Roviello Giandomenico;
2016
Abstract
Hyperthermic intraperitoneal chemotherapy (HIPEC), a strategy combining maximal cytoreductive surgery and maximal regional chemotherapy, has been applied to treat ovarian cancer resulting in long-term survival rates in selected patients. However, the status of HIPEC in ovarian cancer remains an experimental procedure, given the many variables among the data and trials reviewed, to enable us to derive strong conclusions about its role from this overview. In this review we discuss treatment with HIPEC in patients with ovarian cancer and future prospective of its use in clinical setting. HIPEC is an effective tool in the treatment of selected patients with peritoneal carcinomatosis from ovarian cancer. Unfortunately, due to the lack of randomised trials, the evidence of HIPEC is very limited. Future randomised studies are awaited to define the role and clinical impact of HIPEC in ovarian cancerFile | Dimensione | Formato | |
---|---|---|---|
Int J Hyperthermia.pdf
Accesso chiuso
Dimensione
6.75 MB
Formato
Adobe PDF
|
6.75 MB | Adobe PDF | Richiedi una copia |
Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for treatment of ovarian cancer.pdf
Accesso chiuso
Dimensione
1.19 MB
Formato
Adobe PDF
|
1.19 MB | Adobe PDF | Richiedi una copia |
I documenti in FLORE sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.